STOCK TITAN
  1. Home
  2. News
  3. ENSC

Ensysce Biosciences, Inc. - ENSC STOCK NEWS

Welcome to our dedicated news page for Ensysce Biosciences (Ticker: ENSC), a resource for investors and traders seeking the latest updates and insights on Ensysce Biosciences .

Our selection of high-quality news articles is accompanied by an expert summary from Rhea-AI, detailing the impact and sentiment surrounding the news at the time of release, providing a deeper understanding of how each news could potentially affect Ensysce Biosciences 's stock performance. The page also features a concise end-of-day stock performance summary, highlighting the actual market reaction to each news event. The list of tags makes it easy to classify and navigate through different types of news, whether you're interested in earnings reports, stock offerings, stock splits, clinical trials, fda approvals, dividends or buybacks.

Designed with both novice traders and seasoned investors in mind, our page aims to simplify the complex world of stock market news. By combining real-time updates, Rhea-AI's analytical insights, and historical stock performance data, we provide a holistic view of Ensysce Biosciences 's position in the market.

News
Ensysce Biosciences Secures $1.7 Million Convertible Note Financing
Rhea-AI Summary
Ensysce Biosciences, Inc. has entered into a securities purchase agreement with investors for an aggregate investment of $1.7 million. The funding will support the clinical development of their lead product and advance their unique technologies. The Notes are convertible into shares of Ensysce common stock at a conversion price of $1.5675 and the Warrants have the right to purchase up to 1,255,697 shares of common stock at an exercise price of $1.5675.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-7.09%
Tags
none
-
News
Ensysce Biosciences Announces Poster Presentation at the AAPS 2023 PharmSci 360
Rhea-AI Summary
Ensysce Biosciences to showcase collaborative work with Quotient Sciences at AAPS PharmSci 360 event
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
6.48%
Tags
none
-
News
Ensysce Biosciences Releases "Highlights Video" of PAINWeek 2023 Symposium
Rhea-AI Summary
Ensysce Biosciences highlights PF614 and PF614-MPAR at PAINWeek Symposium
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
7.46%
Tags
none
News
Ensysce Biosciences to Chair the Fierce New Product Planning Summit 2023
Rhea-AI Summary
Ensysce Biosciences, Inc. (NASDAQ:ENSC) will present at the Fierce New Product Planning Summit 2023 on October 16-17, 2023 in Boston, MA. Geoff Birkett, CCO of Ensysce, will deliver opening remarks and present a case study on drug launch process. Ensysce is preparing for the launch of its first product, PF614, in a new class of analgesics.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-5.26%
Tags
none
-
News
Ensysce Biosciences Announces Completion of Site Initiation Visit for PF614-201 Clinical Study
Rhea-AI Summary
Ensysce Biosciences completes Site Initiation Visit for PF614-201 study, bringing it closer to Phase 3. Study aims to evaluate time of onset for PF614 and determine optimal prescribing options for surgical patients. Results expected in late 2023.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
2.76%
Tags
clinical trial
-
News
Ensysce Biosciences to Host Research and Development FAQ Session Following PAINWeek Symposium on September 21, 2023
Rhea-AI Summary
Ensysce Biosciences to host R&D FAQ Session to discuss recent developments in their approach to delivering the Next Generation of analgesics. The event received positive feedback from attendees.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-4.65%
Tags
conferences
News
Ensysce Biosciences Completes Scale Up Manufacture of PF614 to Support Phase 3 Studies
Rhea-AI Summary
Ensysce Biosciences completes scale up manufacturing for lead drug candidate PF614, positioning the company for commercialization. Clinical milestones met include bioequivalence to Oxycodin with lower abuse potential. Manufacturing of over 10kg of active pharmaceutical ingredient completed.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-4.35%
Tags
clinical trial
-
News
Ensysce Presents "A New Generation of Safer Pain Treatments"
Rhea-AI Summary
Ensysce Biosciences presents clinical data at PAINWeek Symposium on new approaches to treat severe pain, addressing opioid crisis and improving drug safety
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
3.85%
Tags
none
-
News
Biosciences to Present at the H.C. Wainwright 25th Annual Global Investment Conference
Rhea-AI Summary
Ensysce Biosciences invited to present at H.C. Wainwright 25th Annual Global Investment Conference
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
1.67%
Tags
conferences
News
Ensysce Biosciences to Present Clinical Dataset at Major PAINWeek Scientific Symposium
Rhea-AI Summary
Ensysce Biosciences, Inc. (NASDAQ:ENSC) will host a symposium at PAINWeek to present clinical data on their next-generation agents designed to reduce opioid abuse and prevent overdose deaths. Leading authorities on pain, opioid use, and drug development will be speaking at the event.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
4.21%
Tags
conferences clinical trial
Stock ENSC logo
Ensysce Biosciences, Inc.

OTC:ENSC

ENSC Rankings

N/A Ranked by Market Cap
N/A Ranked by Stock Gains
N/A Ranked by Dividends

ENSC Stock Data

4.61M
7.14M
5.55%
2.32%
0.24%
Pharmaceutical Preparation Manufacturing
Manufacturing
Link
United States of America
LA JOLLA

About ENSC

ensysce biosciences, san diego, ca, is an integrated drug delivery company for both small and large molecules. to overcome the major problem of non-medical use of opioid products, ensysce is using its prodrug technology to improve abuse deterrent properties. the tap bio-md™ abuse deterrent and mpar™ overdose resistant pain platforms, with worldwide intellectual patent protection, eliminate the ability to abuse opioid products by the non-oral route. this abuse is the fastest growing drug problem in the u.s. and it leads to billions in healthcare costs annually. for additional information about ensysce biosciences please visit www.ensysce.com.